811867-65-9

Upstream product

• 811867-64-8 (8-bromo-2H-chromen-2-yl)methanol 
• 811867-16-0 Ddz-propargylamine 
• 39508-01-5 (3’,5’-dimethoxy-1,1-dimethylbenzyloxy)carbonyl azide 
• 811867-63-7 Acetic acid 8-bromo-2H-chromen-2-ylmethyl ester 
• 811867-62-6 Toluene-4-sulfonic acid 8-bromo-2H-chromen-2-ylmethyl ester 
• 811867-61-5 Toluene-4-sulfonic acid 2-(2-bromo-6-vinyl-phenoxy)-but-3-enyl ester 
• 811867-45-5 3-bromo-2-hydroxy styrene 
• 1829-34-1 2-hydroxy-3-bromobenzaldehyde 
• 95-56-7 2-hydroxybromobenzene 

Downstream Products

• 874336-10-4 [3-(2-hydroxymethyl-chroman-8-yl)-propyl]-carbamic acid α,α-dimethyl-3,5-dimethoxybenzyl ester 

Relevant academic research and scientific papers

Macrocyclic Modulators of the Ghrelin Receptor

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

Intermediates for macrocyclic compounds

The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME

The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.